INmune Bio appoints Sanofi rare-disease GM and biopharma BD veteran to board

Inmune Bio, Inc.

Board appointed R. Duane Clark II (Sanofi rare-disease GM) and James Sapirstein (CEO of Cocrystal) as independent directors.
Each director gets option for 100,000 shares (36-month vest) plus $50,000 annual cash retainer.
Board enlarged to seven; both join Nominating and Corporate Governance Committee.
Appointments target rare-disease commercialization for Ebstrocel and strategic partnering across pipeline.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.